drugset
drugset / Trial / NCT04604496

STUDY OF PF-06882961 IN PARTICIPANTS WITH AND WITHOUT VARYING DEGREES OF HEPATIC IMPAIREMENT

NCT04604496 ↗

Phase 1 Completed 24 enrolled Pfizer
Non-randomizedParallel-groupSingle-blindBasic science

Summary

The current study is proposed to evaluate whether there is any clinically meaningful effect of hepatic impairment on the plasma Pharmacokinetic (PK) of PF-06882961

Timeline

Start
2020-12-30
Primary completion
2022-01-10
Completion
2022-01-10

Drugs

EvaluationDrugModalityDoseRoute
Subject Danuglipron Small molecule 20 mg Oral

Indications

No indication recorded.